Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of DMD based on clinical phenotype with increased serum creatine kinase~2. Documented mutation in the Dystrophin gene associated with DMD that is amenable to exon 51 skipping~3. Ambulatory male, able to walk independently for at least 10 meters in 10 seconds or less at the time of Screening visit (performed as part of the NSAA)~4. Stable pulmonary and cardiac function, as measured by:~   1. Reproducible percent predicted forced vital capacity (FVC) ≥50%~  2. Left ventricular ejection fraction (LVEF) \>55% in patients \<10 years of age and \>45% in patients ≥10 years of age, as measured (and documented) by echocardiogram~5. Currently on a stable corticosteroid therapy regimen, defined as initiation of systemic corticosteroid therapy occurred ≥6 months prior to Screening, and no changes in dosing ≤3 months prior to Screening visit~Exclusion Criteria:~1. Cardiac insufficiency:~   1. Severe cardiomyopathy that, in the opinion of the Investigator, prohibits participation in this study; however, cardiomyopathy that is managed by angiotensin-converting-enzyme (ACE) inhibitors or beta blockers is acceptable provided the patient meets the LVEF inclusion criterion~  2. Any other evidence of clinically significant structural or functional heart abnormality~  3. A cardiac troponin I value \> 0.2 ng/mL~2. Need for daytime mechanical or non-invasive ventilation OR anticipated need for daytime mechanical or non-invasive ventilation within the next year, in the opinion of the Investigator. Nighttime non-invasive ventilation is permitted~3. Received prior treatment with drisapersen or with an investigational peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)~4. Received prior treatment with gene therapy for DMD~5. Received treatment with ataluren or eteplirsen within the 14 weeks prior to the planned Baseline biopsy collection~6. Received any investigational drug within 3 months or 5 half-lives, whichever is longer, prior to the planned Baseline biopsy collection

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- WVE-210201 (3 mg/kg) (Type: EXPERIMENTAL): Weekly IV administrations of WVE-210210 at 3 mg/kg
- WVE-210201 (4.5 mg/kg) (Type: EXPERIMENTAL): Weekly IV administrations of WVE-210210 at 4.5 mg/kg
- Placebo (Type: PLACEBO_COMPARATOR): Weekly IV administrations of phosphate buffered saline solution visually identical in appearance to WVE-21021

Based on this trial design, predict the completion outcome and termination type (if applicable).